Pacific Biosciences of California Inc [PACB] Stock trading around $5.74 per share: What’s Next?

Pacific Biosciences of California Inc [NASDAQ: PACB] stock went on a downward path that fall over -13.94% on Friday, amounting to a one-week price decrease of less than -13.55%. The company report on February 15, 2024 at 4:05 PM that PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results.

PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2023.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Over the last 12 months, PACB stock dropped by -48.24%. The one-year Pacific Biosciences of California Inc stock forecast points to a potential upside of 48.38. The average equity rating for PACB stock is currently 1.73, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $1.54 billion, with 267.44 million shares outstanding and 253.36 million shares in the current float. Compared to the average trading volume of 7.02M shares, PACB stock reached a trading volume of 18093852 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Pacific Biosciences of California Inc [PACB]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PACB shares is $11.12 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PACB stock is a recommendation set at 1.73. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Stephens have made an estimate for Pacific Biosciences of California Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on December 14, 2023.

The Average True Range (ATR) for Pacific Biosciences of California Inc is set at 0.54, with the Price to Sales ratio for PACB stock in the period of the last 12 months amounting to 7.66. The Price to Book ratio for the last quarter was 1.94, with the Price to Cash per share for the same quarter was set at 2.36.

PACB Stock Performance Analysis:

Pacific Biosciences of California Inc [PACB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.55. With this latest performance, PACB shares dropped by -9.75% in over the last four-week period, additionally sinking by -45.33% over the last 6 months – not to mention a drop of -48.24% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PACB stock in for the last two-week period is set at 36.34, with the RSI for the last a single of trading hit 34.05, and the three-weeks RSI is set at 38.26 for Pacific Biosciences of California Inc [PACB]. The present Moving Average for the last 50 days of trading for this stock 7.87, while it was recorded at 6.34 for the last single week of trading, and 9.96 for the last 200 days.

Insight into Pacific Biosciences of California Inc Fundamentals:

Pacific Biosciences of California Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.27 and a Current Ratio set at 12.21.


With the latest financial reports released by the company, Pacific Biosciences of California Inc posted -0.36/share EPS, while the average EPS was predicted by analysts to be reported at -0.33/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -9.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PACB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pacific Biosciences of California Inc go to -1.00%.

Pacific Biosciences of California Inc [PACB] Institutonal Ownership Details

The top three institutional holders of PACB stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in PACB stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in PACB stock with ownership which is approximately 5.8325%.